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Abstract
Background: Recombinant human lactoferrin (rhLF) has previously suggested serving as food additive due to
the natural iron binding properties that provide anti-microbial activity. Recombinant cows have been produced that
express hLf in milk. However, the potential allergenicity of hLf has not been previously assessed. This research is
conducted to evaluate the potential allergenicity of rhLF as a prerequisite for food use.
Methods: A comparison was made of the bioactivity, physicochemical properties and glycosylation profile between rhLF and natural hLF. The amino acid sequence of hLf was compared to known allergens. Additionally, the
stability of hLf in pepsin and a human serum IgE test was conducted.
Results: The amino acid identity between rhLF and the minor allergen bovine lactoferrin was 71.4%. However,
every human is exposed to hLf constantly without demonstrated allergies. The rhLF was digested rapidly by pepsin
and was not specifically bound by IgE using serum from patients who are allergic to egg and milk.
Conclusion: Based on these results, the potential allergenicity of rhLF as produced in bovine milk is quite low.
It may be added into formula powder or food to improve nutrition composition.
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deficiency [20]. It has also been proposed for use as a food additive [21]
to reduce microbial spoilage.

Introduction

Large-scale production of hLF is necessary to meet the potential
demand for its many uses. Although several efficient methods have
been used to purify hLF from breast milk [22-26], its supply is quite
limited, expensive and there is concern regarding the potential for
naturally purified hLF to transmit disease vectors such as hepatitis,
human immunodeficiency virus and many other difficult to detect
viral diseases. These obstacles limit application of this useful protein.
Recent developments in biotechnology have allowed production
of recombinant hLF (rhLF) using transformed mammalian cells in
culture and by transformed bacteria in fermentation [27-29]. However,
the yields have been low and since hLF is a highly folded, cross-linked
and glycosylated protein, there has not been good success. A recent
publication demonstrated successful production of rhLF in transgenic
mice with production targeted to the mammary gland [30,31]. A
previous attempt to produce rhLF in rice has so far not been fully
successful as the plant glycosylation system modifies added asparagine
linked glycans differently than mammalian cells and regulators of
GMO’s (Genetically Modified Organism’s) have not approved the GM

pepsin stability; serum screen; Allergenicity

Human lactoferrin (hLF) is known to be a multifunctional protein
of the transferrin family. It is a glycoprotein of approximately 80KDa
and is present in various human secretory fluids including milk, saliva,
tears and nasal secretions as well as being abundant in neutrophils [14]. The hLf protein includes 703 amino acids as a single polypeptide
chain that folds into two similar globular lobes—C- and N-terminal
regions. The structure is maintained by multiple intra-chain disulfide
bonds and the lobes are connected by a short α-helical region. The
isoelectric point of hLf is 8.7 and there are two iron binding sites and 5
potential asparagine-linked glycosylation sites in the molecule [5]. The
degree of glycosylation of the protein varies with the tissue of expression
and the metabolic status of the producing cells [6]. Each lactoferrin
molecule can reversibly bind two ions of iron with high affinity, but
it may also bind zinc, copper or other metals with lower affinity [7].
After combining with iron, it forms a reddish complex. The affinity for
iron is 300 times higher than that of transferrin, although the amino
acid sequences are 60% identical [8]. The characteristics of hLF were
first published in 1984 and the similarities to transferrin were noted [5].
The concentration of lactoferrin in human milk is approximately 7 g/L,
much higher than in milk of non-primate species of mammals.
Human lactoferrin has been demonstrated to have antibacterial,
antiviral, anti-inflammatory and antioxidant properties [9-16]. It can
interact with human cells to modulate the inflammatory process and
innate defense reactions [17]. Lastly, dietary hLF provides an important
mechanism for efficient iron absorption, especially in the neonate, as
well as promoting intestinal epithelial cell growth [17].
Researchers have considered using hLF in a wide variety of
applications due to its bioactivities. Potential applications include
the prophylactic treatment of inflammatory disease [18,19] and iron
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(Genetically Modified) rice as acceptable. Together the data suggested
that utilization of transgenic expression of rhLF in bovine mammary
glands might provide an efficient mechanism for industrial scale
production of hLF.
Investigators at China Agricultural University produced two
transgenic cows, one that secreted rhLF at 2.5 g/L and a second that
secreted rhLF at 3.4 g/L in their milk. Transformation was accomplished
through microinjection of a bacterial artificial chromosome (BAC)
containing a copy of genomic clone (~150 kb) of hLF into bovine
fibroblasts, followed by somatic cell cloning and transfer to the uterus of
recipient cows with a small number of transgenic calves being produced
[32]. In previous studies of the rhLF transgenic cows the composition
of milk and milk powder from transgenic cows were compared to
that from non-transgenic cows. The results did not demonstrate any
significant differences with the exception of the presence of high levels
of rhLF in the transgenic milk [32,33]. Biochemical characterization
of rhLF and hLF demonstrated slight differences in molecular weight,
with rhLF being slighly lower than hLF. The difference may be due to
small variations in glycosylation profiles between the two proteins.
Detailed characterization of glycosylation patterns of rhLF expressed
in bovine mammary glands demonstrated diverse structures [34]. The
results indicated that hLF and rhLF were glycosylated at the same two
sites: Asn138 and Asn479. The differences between rhLF and hLF in
N-glycosylation profiles were consistent with the widely held view
that glycosylation is species- and tissue/cell- specific [34]. Importantly,
neither glycan structures (fucose and xylose substitutions at specific
sites) that are known to be responsible for irrelevant IgE binding in
some subjects [35] nor alpha-galactose that has been demonstrated to
cause adverse immunological reactions [36] was detected on rhLF [37].
The susceptibility to proteolysis of rhLF was studied and compared
with that of natural hLF [32]. Results of the in vitro tests indicated that
pepsin can digest rhLF completely in 60 min, which was similar to that
of natural hLF.
Finally, the in vitro antibacterial effect of rhLF, iron binding and
releasing properties was researched and the comparison was conducted
between rhLF and hLF. The results also demonstrated that rhLF’s
properties are similar to hLF [32].
As a transgenic protein, it is necessary to evaluate the allergeinicity
of rhLF expressed in GM cows according to international standard.
In this study a bioinformatics analysis, tests of the stability of rhLF in
pepsin and the serum reactivity tests were conducted to evaluate rhLF’s
potential allergenicity. An important under-stated consideration in the
Codex guidelines and various country regulations is the history of safe
use [38,39]. Since hLF is produced in secretory glands of the human
body including mammary, lacrimal and salivary glands as well as in
polymorphonuclear leukocytes, human exposure to the protein is not
only common, but constant. There are no reports of allergy to this selfprotein. Thus the likelihood of allergy to an exogenous source of the
protein, if it has the same amino acid sequence is negligible.

Materials and Methods
Bioinformatics analysis
On the basis of the recognized international guidelines for evaluating
GMO’s the allergenicity of rhLF expressed in the milk of transgenic
cow was evaluated simply based on bioinformatics and resistance to
digestion by pepsin. The amino acid sequence comparison for rhLF was
conducted with three databases; FARRP (http://www.allergenonline.
com), SDAP (http://fermi.utmb.edu/SDAP/sdap_src.html) and ADFS
J Aller Ther

(http://allergen.nihs.go.jp/ADFS/), which are widely used in the world
at present [40-42]. The primary methods of evaluation were searches for
“80 amino acid alignments with greater than 35% identity by FASTA”
and “8 amino acid exact matches”. Because of the peptide match of 6
continuous amino acids to known allergens will result in many false
positives [41,42] and produce many random, irrelevant matches [43],
this method was not used in this evaluation.

Stability to pepsin digestion
The digestion resistance of rhLF was tested according to published
methods [44]. Stimulated gastric fluid (SGF) was prepared to include
pepsin purchased from Sigma Chemical (Shanghai, Sigma-Aldrich
China, Inc), with a stated activity of 4220 U/mg of protein as analyzed
by Sigma. In this study a ratio of 20 U of pepsin activity/µg of test
protein, about 5:1 (w/w), was used throughout the study. The other
materials, bovine serum albumin (BSA) and bovine β-lactoglobulin
(BLG) were also obtained from Shanghai, Sigma-Aldrich China, Inc.
for use as control proteins. It has been reported that the BSA is labile
and the BLG is stable to SGF in standard condition [44]. Samples of
digestion products were evaluated in SDS-PAGE with gel staining
according to standard conditions. Images of stained gels were captured
and compared using a gel imaging instrument (GelDoc-It Imaging
System, P/N 95-0441-02, USA).

Human serum test
The results of amino acid sequence comparison showed that rhLF
shares 71.4% identity with bLF and 52.2% identity with ovotransferrin,
two reported allergens [45-48]. As the serum screen is recommended
in some guidelines, human serum tests with rhLF were conducted to
further evaluate the potential allergenicity of rhLF using sera from
donors allergic to milk or egg.
Sera of consenting donors were collected under institutional review
board approval from 12 egg-allergic subjects and 21 milk-allergic
individuals for use in this study. The donors were diagnosed as allergic
to egg or milk based on clinical histories, skin prick test (SPT) and
specific IgE tests (allergic specific Pharmacia UniCAP tests). The level
of egg- or milk- specific IgE in all of the sera samples were >3.5 KUA/L.
Additionally, serum samples from individuals were mixed as serum
pool to be used as negtive control.
Immunoblots were conducted according to the previous protocol
[49-51] with some modifications. In brief, the SDS-PAGE was
conducted using 400 ng purified rhLF, bLF, hLF (kindly provided by
professor Li Ning, Purity: 98%) and 10 μg protein extract prepared
from a standard egg powder (Lot. 1452807v, USA) or from milk
powder (NO. 1549, USA.) with samples loaded in adjacent wells of
the gel. Following separation of proteins by electrophoresis, proteins
were either stained with Coomassie blue or transferred to nitrocellulose
membranes (NC) for immunoblot. Membranes were then rinsed with
distilled water and blocked by submersion in 3% BSA in PBS buffer for
2 h at room temperature. After washing, the blocked membranes were
incubated 2 h at room temperature in individual allergic sera or control
sera, which had been diluted 1:20 (v/v) in blocking buffer 30 min prior
to adding to the membrane. The membranes were washed 6 times in
TBST (0.02M, 0.05% Tween-20), then incubated for 1 h in monoclonal
mouse anti- human IgE conjugated with horseradish peroxidase (HRP)
(kindly provided by professor Li Ning) that was dilluted 1:8000 (v/v)
in blocking solution. After 6 washes in TBST solution, detection was
achieved using ECL (enhanced chemiluminescence; Amersham
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BioSciences, Piscataway, NJ; No. RPN2106), with exposure for 3 min
on the X-ray films.

Results
Bioinformatics comparison
Results of the overall FASTA alignment demonstrated that
rhLF shares 71.4% identity to bovine lactoferrin (bLF), 52.2% to
ovotransferrin and 51.9% to ovotransferrin precursor, using the FARRP
allergen database (Figure 1). Additionally the results of “80 amino acid
alignments” showed the sequence of rhLF contains 532 sliding 80 amino
acid alignments hit >35% to bLF or ovotransferrin or ovotransferrin
precursor using the sliding window search on the FARRP website
(Figure 1).

Pepsin stability of rhLF
The results if digestion experiments are shown in figure 2. The
samples of BSA were digested completely in SGF in 15 s and BLG
samples were still clearly visible after 60 min digestion by pepsin. The
rhLF was digested in 15 s by pepsin as found in a previous study [32].

Human serum tests
The results of Bioinformatics comparison suggested rhLF might act
as a cross-reactive allergen for some consumers allergic to bovine milk
or hen’s eggs and based on guideline recommendations, human serum
testing should be performed. However, since hLF is widely expressed
in every human, and there are no data to support subjects allergic to
human lactoferrin, there is no risk and there should not be a need to
perform serum tests. In order to satisfy regulatory requirements and in
anticipation of questions from consumers or regulators, a decision was
made to test serum IgE binding.
As shown in figure 3, after SDS-PAGE and stained with coomassie
brilliant blue, there are mainly 4 protein bands, which are about 65
KD (Bovine Serum Albumin, BSA), 34 KD, 26 KD (Caseins, CAS)
and 18 KD (β-lactoglobulin, LG) in the extraction of standard milk
powder. 10 protein bands were evident in the egg powder and their
molecular weight were approximately 230 KD, 150 KD, 130 KD, 83 KD
(Ovotransferrin, OVT), 72 KD, 60 KD, 45 KD (Ovalbumin, OVA), 40
KD, 34 KD, 28 KD (Ovomucoid, OVM). Since the standard egg powder
used in this study was whole egg powder, it is assumed that the high
weight molecules are from the yolk. The three obvious banding in lane
3, 4 and 5 were rhLF, hLF and bLF respectively, and their MW were all
about 80 KD.
The immunoblot results are shown in figure 4, there was no visible
binding band in the membrane that incubated with control serum
Hit
#

Defline

from healthy donors (Figure 4B). The notable IgE binding reaction was
detected in the protein bands of 150 KD, 83 KD, 45 KD, 34 KD in egg
powder and of 65 KD, 26 KD, 18 KD in milk powder. These proteins
maybe the important allergens, which named as ovotransferrin (OVT),
ovabumin (OVA), ovomucoid (OVM), bovine serum albumin (BSA),
casein (CAS) and lactoglobulin (LG) in egg and milk (Figures 4C and
4D). This is in accordance to previous study [52]. And finally, there was
no visible IgE binding reaction to purified rhLF, hLF and bLF in all of
the test serum samples (Figures 4C and 4D). Because of the sensitivity
of this immunoblot and detection method which used ECL, IgE should
be detectable at the level of pg and the banding reaction of protein and
its antibody was detected in our preliminary experiment when the
loaded dose was 40 ng (Figure 4A). So the lack of apparent IgE binding
to hLF and rhLF demonstrates that there would not be any IgE binding
to the rhLF expressed in cow’s milk.

Discussion
As one of functional proteins that is secreted by multiple tissues of the
human body, hLF is always present in various organs and fluids (blood,
lymph, milk, saliva, semen, and tears) of humans. Dietary exposure is
common for infants who are breast fed as well as continuing exposure
through saliva and bile. Exposure to lactoferrin certainly starts before
birth. However, no evidence of allergy to human lactoferrin has been
reported. It’s common and high expression level in various fluids and
in PMNs is expected to lead to immune tolerance rather than allergy
or other adverse immune responses to self [53]. Immune tolerance is
primarily formed in the embryonic period and soon after birth when
the immature T lymphocyte and B lymphocyte contact the self-protein
or the other substance and this can be maintained throughout life.
In previous studies it was demonstrated that the rhLF expressed in
the milk produced from transgenic cows has similar in antimicrobial,
iron binding and growth promoting activity of epithelial cells [32].
An earlier study of the glycosylation patterns of rhLF were compared
to natural hLF [34]. The Cross-reactive Carbohydrate Determinant
(CCD) type glycans (xylose or fucose substituted complex N-linked
glycans) and alpha-gal are often considered as potential allergenic
carbohydrates in protein [54-56]. The results show that only a small
amount of Neu5Gc was detected by HPLC and no other antigenic
carbohydrates were found [34]. And the glycosylation profile of rhLF
was similar to hLF.
In recent years, a number of international organizations, including
the Food and Agricultural Organization (FAO) and World Health
Organization (WHO) and Codex Alimentarius Commission (CAC)
developed recommendations for the evaluation of GMO’s for potential
allergenicity in foods. The International Food Biotechnology Council
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The amino acid sequence of rhLF is GRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQAIAENRADAVTLDGGFIYEAGLAPYKLRPVAAEVYGTERQPRTHYYAVAVVKKGGSFQLNELQGLKSCHTGLRRTAGWNVPIGTLRPFLNWTGPPEPIEAAVARFFSASCVPGADKGQFPNLCRLCAGTGENKCAFSSQEPYFSYSGAFKCLRDGAGDVAFIRESTVFEDLSDEAERDEYELLCPDNTRKPVDKFKDCHLARVPSHAVVARSVNGKEDAIWNLLRQAQEKFGKDKSPKFQLFGSPSGQKDLLFKDSAIGFSRVPPRIDSGLYLGSGYFTAIQNLRKSEEEVAARRARVVWCAVGEQELRKCNQWSGLSEGSVTCSSASTTEDCIALVLKGEADAMSLDGGYVYTAGKCGLVPVLAENYKSQQSSDPDPNCVDRPVEGYLAVAVVRRSDTSLTWNSVKGKKSCHTAVDRTAGWNIPMGLLFNQTGSCKFDEYFSQSCAPGSDPRSNLCALCIGDEQGENKCVPNSNERYYGYTGAFRCLAENAGDVAFVKDVTVLQNTDGNNNEAWAKDLKLADFALLCLDGKRKPVTEARSCHLAMAPNHAVVSRMDKVERLKQVLLHQQA
KFGRNGSDCPDKFCLFQSETKNLLFNDNTECLARLHGKTTYEKYLGPQYVAGITNLKKCSTSPLLEACEFLRK
Figure 1: Results of bioinformatics analysis of hLF. It was compared to allergens contained in the FARRP allergen database, version 11.
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A
97.4KD
BSA
pepsin

66.2KD
43KD

31KD
20KD

B
97.4KD
66.2KD
43KD

pepsin

Figure 4: Results of representative IgE Immunoblots from samples of
standard egg and milk. Picture A was the positive control of rhLF and hLF
using specific antibody to rhLF and hLF. The order of the laoded samples in
picture A were Lane 1: recombinant human lactoferrin (rhLF, 40 ng), Lane
2: human lactoferrin (hLF, 40 ng), Lane 3: ddH2O (15 µl). The order of the
laoded samples in the picture B was as Lane 1: standard milk powder extracts
(10 μg), Lane 2: standard egg powder extracts (10 μg), Lane 3: recombinant
human lactoferrin (rhLF, 40 ng), Lane 4: human lactoferrin (hLF, 40 ng), Lane
5: bovine lactoferrin (bLF, 40 ng). The serum used in picture B to incubate the
membrane was mixture of 5 control sera. In picture C and D, Lane 1: standard
egg powder extracts in C (10 μg) or standard milk powder extracts in D (10 μg),
Lane 2: recombinant human lactoferrin (rhLF, 40 ng), Lane 3: human lactoferrin
(hLF, 40 ng), Lane 4: bovine lactoferrin (bLF, 40 ng). The C was obtained by
incubating the memnrane with a pool contained 12 sera from individual donors
allergic to egg. The level of egg specific IgE in all of the 12 sera samples were
>3.5 KUA/L. Finally, 21 sera donated from individual donors allergic to milk
were mixed to incubate the membrane D, and the level of milk specific IgE in
the serum was also >3.5 KUA/L. In egg and milk there were sevral proteins
binded to specific allergic serum, while the rhLF, hLF and bLF. This indecate
that there was not cross reaction between rhLF and egg, milk.

31KD
20KD
BLG
14.4KD

C
97.4KD
66.2KD
43KD

rhLF
pepsin

31KD
20KD
14.4KD

Figure 2: Result of three proteins digested in a standard in vitro pepsin
digestion assay. The stained gel images show that BSA was rapidly digested,
while BLG was relatively resistant to SGF. The rhLF test protein was digested
in less than 15 s.

Figure 3: SDS-PAGE of standard egg powder and milk powder extracts. Lane
1: standard milk powder extracts (10 μg); Lane 2: standard egg powder extract
(10 μg); Lane 3: recombinant human lactoferrin (rhLF, 400 ng); Lane 4: human
lactoferrin (hLF, 400 ng); Lane 5: bovine lactoferrin (bLF, 400 ng); Lane 6:
molecular weight marker (the standard weight band is 170 KD, 130 KD, 95 KD,
72 KD, 55 KD, 43 KD, 34 KD, 26 KD and 10 KD respectively). The rhLF, hLF
and bLF were detected in the gel at a loaded dose of 400 ng.

J Aller Ther

and the Allergy and Immunology Institute of the International Life
Sciences Institute (IFBC/ILSI) presented a decision-tree approach
to evaluate the potential allergenicity of the exogenous proteins in
genetically modified crops intended for food use [37] in 1996. If the
source of the gene (donor) is known to cause allergies, serum from a
number of individuals allergic to the donor would be used to test for
IgE binding to the protein encoded by the transferred gene. The amino
acid sequence would also be compared to those of known allergenic
proteins and if any eight amino acid segment was identical to a segment
of an allergen, serum from a number of subjects allergic to the source
of the allergenic protein would be used in similar tests. The stability of
the protein would also be tested in pepsin under standard conditions of
fixed concentrations at pH 1.2 as a number of important food allergens
were known to be stable in pepsin. The abundance of the protein and
stability (of function) of the protein under heated conditions would also
be considered as secondary additional characteristics of possible risk of
allergy. This approach [37] was accepted by scientific panels organized
by the FAO/WHO in 1996 and 2000 during joint Consultations on the
safety assessment of genetically modified foods of plant origin. During
an additional consultation of scientists, the FAO/WHO 2001 suggested
a modified decision tree that changed criteria and broadened some
of the previous approaches [57]. For sequence comparisons identity
matches of >35% over any segment of 80 or more amino acids or any
100% identity match of six or more contiguous amino acids significant
would trigger specific IgE testing using sera from individuals allergic
to the source of the matched allergen. In addition, targeted serum
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testing was suggested, where up to 50 individual donors allergic to
broad taxonomic categories would be tested (e.g. those allergic to foods
or pollen of various monocotyledons would be used if the gene was
from any monocot). However, targeted screening would not be used if
the gene was from a bacterium. Stability to digestion of the protein in
pepsin would also be tested, but the using of two pH conditions (1.2
and 2.0) was recommended. The final recommendation was to attempt
to sensitize two species of animals, or one species, but use two routes of
exposure to evaluate the sensitizing potential of the purified GM protein.
The Codex Alimentarius Commission reviewed the FAO/WHO 2001
guidelines among other recommendations and indicated that animal
models have not been proven to be predictive, that the bioinformatics
criteria of >35% identity in 80 amino acid overlap by FASTA would be
considered positive, that any short amino acid identity matches should
be scientifically justified and that pepsin digestion could be performed
at pH 1.2 or 2.0 [58]. The Codex Alimentarius Commission did not
recommend using targeted serum testing, but only specific testing to
evaluate proteins expressed by genes taken from allergenic sources
or proteins exceeding the bioinformatics criteria (above) [58,59].
Regulatory agencies in many countries including Canada, Australia
and New Zealand, Japan, South Korea, Taiwan and the U.S. follow
the Codex guidelines. The European Food Safety Authority (EFSA)
[60] has developed slightly more explicit guidelines that are intended
to be followed by members of the European Union [61]. The issue of
heat stability has not been clearly demonstrated as predictive for food
allergy as the relationship only appears to be useful for predicting risk
if the unheated protein binds IgE or causes allergic reactions, but the
recombinant protein expressing in a food source is always heated [62].
Then testing stability of IgE binding or elicitation of allergic reactions
with heated protein should be used in risk assessment.
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